Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06481397 · ClinicalTrials.gov registry record · NA
OSCAR I STUDY - The ONCObind CTC Removal Study
A NA study, sponsored by ExThera Medical Corporation.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT06481397 is a NA study that has completed, run by ExThera Medical Corporation. The registered enrollment target is 5 participants.
The verdict
NCT06481397, a NA study, has completed, sponsored by ExThera Medical Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is a Prospective Single Arm Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in metastatic PDAC refractory to systemic therapy. Site selection will be dependent upon the site's familiarity with extracorporeal blood purification platforms as well as the diagnosis and management of PDAC. Adults (18 years old and older, ECOG PS of equal or less than 2) with a diagnosis of PDAC as defined histologically (microscopically) as a "pancreatobiliary type" adenocarcinoma with at least 5 U/mL CTCs in peripheral blood and/or portal vein.
Interventions
- DEVICE ONCObind (Onco-Seraph) 100 Filter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-08-29 |
| Est. Completion | 2024-10-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06481397
The ClinicalTrials.gov registry entry for NCT06481397 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ExThera Medical Corporation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ONCObind (Onco-Seraph) 100 Filter is the first listed.
NCT06481397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06481397 about?
NCT06481397 is a clinical study titled "OSCAR I STUDY - The ONCObind CTC Removal Study". This study is a Prospective Single Arm Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in metastatic PDAC refractory to systemic therapy. Site selection will be dependent upon the site's familiarity with ...
What is the current status of trial NCT06481397?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2024-08-29. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT06481397?
The interventions under investigation include: ONCObind (Onco-Seraph) 100 Filter (DEVICE).
Who is sponsoring clinical trial NCT06481397?
This trial is sponsored by ExThera Medical Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.